NAD: a Foundational Molecule

NAD is a foundational molecule that plays an essential role in many metabolic and cell regulatory processes—the full implications of which are only now being understood. In addition to its demonstrated benefits for treating addiction, depression, and post-traumatic stress, NAD has been gaining recognition for its role in combating the effects of aging—and for offering powerful possibilities for the treatment of chronic diseases, autoimmune disorders, chronic fatigue, and neurodegenerative diseases like Alzheimer’s and Parkinson’s. 

NAD Research, Inc. is the only research foundation devoted exclusively to greater scientific understanding of the clinical applications and benefits of NAD—nicotinamide adenine dinucleotide—a foundational molecule found in every cell in the human body.

We are a nonprofit 501-c-3 scientific research organization with an organizational board and an international scientific advisory board, which oversees and directs current and proposed research projects.

Established in 2017, we have already sponsored half-a-dozen basic and applied research studies on the biochemical workings of NAD (see our Publications section), including:

• A pharmacokinetic study of intravenous NAD in healthy volunteers, conducted in collaboration with the Australasian Research Institute and the University of New South Wales (published in Frontiers in Aging Neuroscience).

• An MRI study, conducted in collaboration with the Center For Magnetic Resonance Research at the University of Minnesota, of NAD levels and ATP production in healthy volunteers.

• A case presentation on a Parkinson’s disease patient conducted in collaboration with the Australasian Research Institute and the University of New South Wales (published in On Journ).

• A retrospective study of the effect of intravenous NAD on self-reported cravings for alcohol and opiates resulting in a poster presentation at the Society For Neuroscience 2015.

• A poster presentation at the Society of Neuroscience on the effect of intravenous NAD on a patient with a Parkinsonian tremor. Studies in a Q-1 randomized double-blind, placebo-controlled study of the effect of intravenous NAD in alcohol detox utilizing the standard of care; on the effect of intravenous NAD for patients with post-traumatic stress; and on the effect of intravenous NAD on patients with Alzheimer’s disease.

Although our primary investigative focus is intravenous NAD administration, we are also proposing and exploring the effectiveness of other administration strategies for NAD, including a trans-sphenopalatine ganglia (trans-nasal) delivery system. Our research is conducted at our treatment facility, Springfield Wellness Center, in Springfield, Louisiana, and at research laboratories around the world led by our collaborators and Advisory Board members.

Help us advance medical understanding of this essential molecule. Your donation to NAD Research, Inc., is fully tax-deductible to the extent allowed by law. Give through our fast, secure online payment portal, or make your check payable to NAD Research Inc., and mail to 32872 Cullom Road, Springfield, LA 70464.

Our Mission

NAD Research, Inc., a Louisiana 501(c)(3) nonprofit organization, is to investigate the therapeutic applications of intravenous Nicotinamide Adenine Dinucleotide (NAD+). With our educational division, we can translate our clinical findings through physician education for improved patient outcomes and set standards for the industry.


Board Members


Dave Dooley

Medical Director

Dr. Richard Mestayer, III


Carl Camp


Paula Mestayer


Paula Hotard

AABMM Committee Member

Jade Berg, Ph.D

Advisory Board


Dr. Susan Broom-Gibson, School of Natural and Behavioral Sciences, William Carey University

Dr. Krishna Doniparthi, Functional Medicine of Georgia and NAD of Georgia


Dr. Jade Berg, Australasian Research Institute, University of New South Wales (UNSW)

Dr. Walker B. Dixon, Summit Wellness Center, Portland, OR

Dr. Ross Grant, Australasian Research Institute and School of Medical Sciences, UNSW

Dr. David Lefer, Cardiovascular Center of Excellence and LSU Health Sciences Center in New Orleans

Dr. Richard Mestayer, Springfield Wellness Center, NAD Research, Inc.

Dr. Ken Starr, Ken Starr Wellness Group

Dr. Liz Stuller, EHP Behavioral Health Services, Union Memorial Hospital, Baltimore, MD

Dr. James P. Watson, David Geffen School of Medicine at UCLA

Recent Event

Go to to view the schedule and presentation line-up. By attending the 2020 BR+NAD Brain Restoration Summit you will learn about the newest discoveries of NAD+, November 20-21, 2020. If you are unable to attend this virtual event live, you will be able to purchase tickets to view the recorded version which should be available by the second week of December 2020.